注冊(cè)

?人類乳腺癌qBiomarker體細(xì)胞突變PCR芯片 breast Cancer qBiomarker Mutation PCR Array

科技服務(wù) > 生物芯片實(shí)驗(yàn)服務(wù) > ?人類乳腺癌qBiomarker體細(xì)胞突變PCR芯片 breast Cancer qBiomarker Mutation PCR Array

?人類乳腺癌qBiomarker體細(xì)胞突變PCR芯片 breast Cancer qBiomarker Mutation PCR Array

聯(lián)系購買

配送服務(wù)：

運(yùn)費(fèi) ￥0.00

數(shù)量：

（庫存 9999 件）

產(chǎn)品詳細(xì)

簡介：	Breast Cancer qBiomarker Mutation PCR Array 人類乳腺癌qBiomarker體細(xì)胞突變PCR芯片
提供商：	SABio
服務(wù)名稱：	人類乳腺癌qBiomarker體細(xì)胞突變PCR芯片
地區(qū)：	美國

“英拜為您實(shí)驗(yàn)加速”
技術(shù)服務(wù)網(wǎng)址：http://m.bhsflw.cn/
服務(wù)熱線：400-696-6643、 18019265738
郵箱：daihp@yingbio.com 、 huizhang1228@foxmail.com

Breast Cancer qBiomarker Mutation PCR Array

人類乳腺癌qBiomarker體細(xì)胞突變PCR芯片

Product	Species	Technology	Cat. No.
Breast Cancer qBiomarker Mutation PCR Array	Human	Somatic Mutation	SMH-020A

The Human Breast Cancer qBiomarker Somatic Mutation PCR Array is a translational research tool that allows rapid, accurate, and comprehensive profiling of the top somatic mutations in human breast cancer samples in the following genes: AKT1, APC, BRAF, CDH1, CTNNB1, HRAS, KRAS, NRAS, PIK3CA, and TP53. These mutations warrant extensive investigation to enhance the understanding of carcinogenesis and identify potential drug targets. Numerous research studies have demonstrated the utility of individual and multiple somatic mutation status information in identifying key signaling transduction disruptions. For example, the mutation status of the EGFR and KRAS genes can predict the physiological response to certain drugs targeting these molecules. The Human Breast Cancer qBiomarker Somatic Mutation PCR Array, with its comprehensive content coverage, is designed for the study of mutations in the context of breast cancer and has the potential for discovery and verification of drug target biomarkers for this cancer type and other cancer types in which these mutations have been identified. This array includes 84 DNA sequence mutation assays designed to detect the most frequent, functionally verified, and biologically significant mutations in human breast cancer. These mutations were chosen from curated, comprehensive somatic mutation databases and peer-reviewed scientific literature, and represent the most frequently recurring somatic mutations compiled from over 6000 breast cancer samples. The simplicity of the product format and operating procedure allows routine somatic mutation profiling in any research laboratory with access to real-time PCR instruments
人類乳腺癌qBiomarker體細(xì)胞突變PCR芯片是一個(gè)翻譯研究工具,用于快速,準(zhǔn)確,全面剖析人類乳腺癌前體細(xì)胞突變的基因: AKT1, APC, BRAF, CDH1, CTNNB1, HRAS, KRAS, NRAS, PIK3CA, and TP53.這些突變保證廣泛的研究,以提高致癌作用的理解和鑒定潛在的藥物靶點(diǎn)。已有許多研究通過單個(gè)和多個(gè)體細(xì)胞突變狀態(tài)信息鑒定關(guān)鍵信號(hào)轉(zhuǎn)導(dǎo)中斷。例如,EGFR和KRAS基因的突變狀態(tài)可以預(yù)測(cè)某些藥物針對(duì)這些分子的生理反應(yīng)。人類乳腺癌qBiomarker體細(xì)胞突變PCR芯片以其全面的內(nèi)容覆蓋范圍，用于研究乳腺癌的環(huán)境突變且有潛力用于發(fā)現(xiàn)靶向藥物的生物標(biāo)記和驗(yàn)證這些癌癥和其他這些突變已確定的癌癥。這個(gè)芯片包含84個(gè)DNA突變序列用于檢測(cè)在人類乳腺癌中最頻繁的、功能驗(yàn)證的、有生物學(xué)重要意義的突變。這些突變的選擇根據(jù)全面的體細(xì)胞突變數(shù)據(jù)庫和同行評(píng)審的科學(xué)文獻(xiàn)，代表最頻繁重復(fù)編譯的體細(xì)胞突變匯編自超過6000個(gè)乳腺癌樣本。簡單的產(chǎn)品模式和操作程序讓任何一個(gè)具備實(shí)時(shí)定量PCR儀的實(shí)驗(yàn)室都可進(jìn)行常規(guī)的體細(xì)胞突變分析。

AKT1: 1 Assay
The mutation assay detects the best known AKT1 mutation, c.49G>A, p.E17K. This is a PH domain mutation that results in constitutive targeting of AKT1 to plasma membrane.
APC: 1 Assay
The most commonly detected APC inactivation mutations are mainly composed of truncation mutations (due to nonsense mutations and frameshift mutations) and point mutations between codons 1250 and 1578.
BRAF: 2 Assays
There are two major classes of BRAF mutations. One class leads to increased BRAF kinase activity, such as the p. V600E mutation. The other class leads to impaired kinase activity, such as the p.G469A mutation.
CDH1: 3 Assays
The top CDH1 mutations either are missense mutations or frameshift mutations that lead to C-terminal truncation and secreted E-cadherin fragments.
CTNNB1: 1 Assay
The most frequently detected CTNNB1/beta-catenin mutations result in abnormal signaling in the WNT signaling pathway. The mutated codons are mainly several serine/threonine residues targeted for phosphorylation by GSK-3beta.
HRAS: 1 Assay
The most important HRAS mutations identified in cancers occur at codons 12
KRAS: 5 Assays
The mutation assays include the most frequently occurring mutations in KRAS codons 12, 13, and 61. Mutations at these positions result in reduced intrinsic GTPase activity and/or cause KRAS to become unresponsive to RasGAP.
NRAS: 1 Assay
The most important NRAS mutation in breast cancer occurs at codon 61.
PIK3CA: 13 Assays
The most frequently occurring PIK3CA mutations mainly belong to two classes: gain-of-function kinase domain activating mutations and helical domain mutations that mimic activation by growth factors.
TP53: 56 Assays
The most frequently detected somatic mutations in TP53 are largely composed of DNA-binding domain mutations which disrupt either DNA binding or protein structure

Overview of the qBiomarker Somatic Mutation PCR Array / Assay Protocol

Overview of the qBiomarker Somatic Mutation PCR Array / Assay Protocol.
The procedure involves DNA extraction (QIAGEN QIAamp DNA Mini Kit or FFPE Tissue Kit is recommended), an optional amplification (QIAGEN REPLI-g kit or REPLI-g UltraFast kit is recommended) step for DNA isolated from fresh samples, qPCR detection on qBiomarker Somatic Mutation PCR Arrays or Assays, and data analysis (using the qBiomarker Somatic Mutation Data Analysis Template). An optional DNA sample QC step immediately before the detection array or assay setup allows the user to qualify the DNA samples.

Principle of Mutant Discrimination with ARMS?